#56993

Date:	**August 01, 2025**
Subject:	**Acurx Pharmaceuticals, Inc. - Reverse Split** **Option Symbol: ACXP** **New Symbol: ACXP1** **Date: 08/05/2025**

Acurx Pharmaceuticals, Inc. (ACXP) has announced a 1-for-20 reverse stock split. As a result of the reverse stock split, each ACXP Common Share will be converted into the right to receive 0.05 (New) Acurx Pharmaceuticals, Inc. Common Shares. The reverse stock split will become effective before the market open on August 5, 2025.

Contract Adjustment

Effective Date:	August 5, 2025
Option Symbol:	ACXP changes to ACXP1
Contract Multiplier:	1
Strike Divisor:	1
New Multiplier:	100 (e.g., for premium or strike dollar extensions 1.00 will equal $100)
New Deliverable Per Contract:	5 (New) Acurx Pharmaceuticals, Inc. (ACXP) Common Shares
CUSIP:	ACXP (New): 00510M203

Pricing

The underlying price for ACXP1 will be determined as follows:

ACXP1 = 0.05 (ACXP)

Disclaimer

investment decisions. Option or futures investors should independently ascertain and evaluate all information concerning this corporate event(s).

The determination to adjust options and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article VI, Sections 11 and 11A. The determination to adjust futures and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article XII, Sections 3, 4, or 4A, as applicable. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, please email the Investor Education team at options@theocc.com. Clearing Member Firms of OCC may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email memberservices@theocc.com.